ACTH Side Effects: What Studies Report

Where the ACTH safety literature actually comes from

Adrenocorticotropic hormone (ACTH, also called corticotropin) is a pituitary peptide whose principal job is to signal the adrenal cortex. Reviews of hypothalamic–pituitary–adrenocortical axis regulation described a closed feedback loop in which hypothalamic signalling drives pituitary ACTH release, ACTH drives adrenal glucocorticoid output, and circulating glucocorticoids then restrain the upstream signals (PMID 15850842). That architecture matters for any discussion of side effects: because ACTH acts almost entirely through the adrenal gland, the adverse-event profile described in the literature is largely a glucocorticoid profile rather than a profile unique to the peptide itself.

Published safety information on ACTH clusters into four separate bodies of work, and they are not interchangeable:

• Physiology and axis regulation — reviews describing how ACTH secretion is controlled and how feedback suppresses it (PMID 15850842).
• Pediatric neurology — clinical studies of ACTH used as a treatment in infantile spasms, including a dedicated cardiac-monitoring study (PMID 35204017, PMID 41240742).
• Endocrine disease — the Cushing syndrome literature, which describes what happens when ACTH and cortisol run high for prolonged periods (PMID 35979805, PMID 39526050).
• ACTH deficiency — oncology and pituitary reports describing the opposite problem, loss of ACTH signalling (PMID 32200950, PMID 37405219).

This page summarises what those publications reported. It does not reproduce dosing schedules, and it does not extrapolate findings from a clinical indication to any other context. For the underlying physiology and terminology, the ACTH course covers the axis in teaching format; this page stays on the safety and adverse-event literature.

Cortisol Excess Effects: What Studies Report

The most thoroughly documented consequence of elevated ACTH activity is hypercortisolism. Reviews of the diagnostic workup of Cushing's syndrome described the clinical picture that prompts screening and the biochemical tests researchers used to confirm cortisol excess, including the distinction between ACTH-dependent and ACTH-independent causes (PMID 35979805). That distinction is the key one for anyone reading about ACTH itself: in ACTH-dependent disease, the driver is excess corticotropin signalling, and the downstream features are the features attributed to glucocorticoid excess.

Reviews of medical therapy in severe hypercortisolism framed marked cortisol excess as a state that clinicians treat urgently rather than observe, and described the drug classes researchers used to lower cortisol production or block its receptor (PMID 33518458). A separate review of glucocorticoid receptor blockers described how receptor-level antagonism was used when reducing cortisol synthesis was insufficient or impractical (PMID 35507245). A 2024 review of new trends in treating Cushing's disease summarised pituitary-directed and steroidogenesis-directed options that researchers have developed for ACTH-driven hypercortisolism (PMID 39526050).

The relevance to a side-effect page is indirect but important: the existence of an entire therapeutic literature aimed at lowering ACTH-driven cortisol indicates that sustained elevation of this axis is treated as a pathological state in the published record, not a benign one.

Thromboembolism

One specific complication has its own dedicated study. Researchers evaluated the safety and effectiveness of rivaroxaban thromboprophylaxis in patients with adrenocorticotropic hormone-dependent Cushing syndrome, a clinical question that only arises because thromboembolic events are treated as an expected hazard of this hormonal state (PMID 41540719). The study population was patients with established ACTH-dependent disease, not healthy volunteers, and the paper addressed anticoagulant safety rather than the natural history of clotting risk.

Cardiac Findings During ACTH Therapy: What Studies Report

The clearest example of prospective safety surveillance during ACTH administration comes from pediatric neurology. A 2025 report examined the cardiac safety of low-dose ACTH therapy in infants treated for infantile spasms, using electrocardiography together with advanced echocardiography to look for changes that routine clinical examination might not detect (PMID 41240742). The study design itself is informative: researchers considered cardiac structure and function a monitoring priority during ACTH treatment, and selected imaging sensitive enough to pick up subclinical signals.

A separate 2022 study assessed the effectiveness of ACTH in patients with infantile spasms, reflecting the clinical setting in which ACTH exposure has been most systematically documented in humans (PMID 35204017). Readers looking for numerical safety outcomes should consult the primary papers; this page does not restate figures beyond the scope of the cited titles and abstracts.

Two caveats appear repeatedly in how this literature should be read. First, the study populations were infants with a specific epilepsy syndrome, and monitoring findings in that group do not describe what happens in other populations. Second, the exposures studied were supervised medical treatments with defined endpoints, and the published cardiac monitoring was part of that clinical framework.

ACTH Deficiency and Axis Suppression: What Studies Report

The mirror image of excess is deficiency, and here the literature is comparatively detailed. Reviews of hypothalamic–pituitary–adrenocortical axis regulation described how glucocorticoid feedback suppresses upstream ACTH secretion, which is the mechanism underlying concern about axis recovery after prolonged glucocorticoid exposure (PMID 15850842).

Immuno-oncology has added a large body of case-level detail. Reviews of checkpoint inhibitor-induced hypophysitis described inflammation of the pituitary with resulting hormone deficiencies, including corticotropin deficiency, as a recognised immune-related adverse event (PMID 32200950). A review of endocrine immune-related adverse events covering adrenal involvement, parathyroid disease, diabetes insipidus and lipoatrophy described how these endocrinopathies were identified and categorised in oncology practice (PMID 35382989). A 2023 case report with literature review described hypothyroidism accompanied by ACTH deficiency during pembrolizumab therapy for lung cancer, illustrating that more than one pituitary axis can be affected at once (PMID 37405219).

These papers are not studies of ACTH administration. They are included because they document what the clinical literature reports when ACTH signalling is lost — the reason clinicians assess adrenal function whenever the corticotropin axis is disturbed in either direction.

Animal Data and Endocrine Endpoints

Preclinical work provides a reminder that hormone axes are routinely measured as safety endpoints rather than efficacy targets. A 2022 rat study assessed reproductive and endocrine effects of artemisinin, piperaquine, and an artemisinin–piperaquine combination, using hormonal endpoints to characterise systemic effects (PMID 36229813). The relevance here is methodological: endocrine panels are standard safety instruments in animal toxicology, and findings in rats do not transfer directly to humans.

What the verified literature does not establish

Several gaps should be stated plainly rather than filled with inference:

• No verified trial in this set examined ACTH given to healthy adults for performance, body composition, recovery, or longevity purposes. The human exposure data reviewed here came from patients with infantile spasms (PMID 35204017) and from endocrine disease populations (PMID 41540719).
• No long-term adverse-event dataset in this verified set followed non-clinical ACTH exposure over months or years.
• No comparative safety data in this set ranked ACTH against synthetic glucocorticoids or other agents outside their studied indications.
• Research-use-only peptide material is not the same product as an approved corticotropin medicine, and none of the verified papers characterised the safety of unapproved preparations.

Where a question has no published answer, the honest description is absence of evidence — not a reassuring inference and not a warning presented as a finding.

How the literature grouped ACTH-related concerns

Reading ACTH safety papers critically

Three habits make this literature easier to interpret. The first is checking whether a paper studied ACTH administration or ACTH dysregulation. Much of what circulates as an "ACTH side effect" list is drawn from Cushing syndrome descriptions, where the hormone was endogenously elevated over long periods (PMID 35979805).

The second is noting the population. Cardiac monitoring findings were generated in infants receiving treatment for a seizure disorder (PMID 41240742), and anticoagulation findings were generated in adults with a hormone-secreting pathology (PMID 41540719). Neither group represents a general population.

The third is distinguishing mechanism from outcome. Axis reviews explained why glucocorticoid feedback can suppress corticotropin output (PMID 15850842), but a mechanism is a hypothesis about what might happen, not a measured event rate. Case reports such as the pembrolizumab-associated ACTH deficiency description document that an event occurred in an individual, without establishing how often it occurs (PMID 37405219).

Taken together, the verified record describes a hormone whose effects are inseparable from cortisol biology, monitored in clinical settings with laboratory testing and, in at least one pediatric study, cardiac imaging. This page is for educational purposes only and is not medical advice; consult a licensed physician about any hormone, medication, or symptom. Nothing here describes a protocol, and nothing here should be read as a characterisation of safety outside the specific studied populations.

References

• Hypothalamic-pituitary-adrenocortical axis regulation (Endocrinology and Metabolism Clinics of North America, 2005)
• Diagnostic workup of Cushing's syndrome (Journal of Neuroendocrinology, 2022)
• Medical therapy in severe hypercortisolism (Best Practice & Research Clinical Endocrinology & Metabolism, 2021)
• Glucocorticoid receptor blockers (Pituitary, 2022)
• New Trends in Treating Cushing's Disease (TouchREVIEWS in Endocrinology, 2024)
• Safety and effectiveness of rivaroxaban thromboprophylaxis in adrenocorticotropic hormone-dependent Cushing syndrome (The Journal of Clinical Endocrinology and Metabolism, 2026)
• Effectiveness of ACTH in Patients with Infantile Spasms (Brain Sciences, 2022)
• Cardiac safety of low-dose ACTH therapy in infantile spasms: Evidence from electrocardiography and advanced echocardiography (Seizure, 2025)
• [Checkpoint inhibitors-induced hypophysitis] (Bulletin du Cancer, 2020)
• Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy (Best Practice & Research Clinical Endocrinology & Metabolism, 2022)
• Hypothyroidism With ACTH Deficiency During Pembrolizumab Therapy for Lung Cancer: Case Report and Literature Review (Cancer Diagnosis & Prognosis, 2023)
• Reproductive and endocrine effects of artemisinin, piperaquine, and artemisinin-piperaquine combination in rats (BMC Complementary Medicine and Therapies, 2022)